Du är här

2014-04-28

Galapagos NV: Galapagos announces management change

Mechelen, Belgium; 28 April 2014 - Galapagos NV (Euronext: GLPG) announces
that Guillaume Jetten will resign as Chief Financial Officer of Galapagos,
effective 1 May 2014. Laure Verhaegen, Vice President Finance, will act as
interim CFO until a replacement has been recruited.

Guillaume Jetten joined Galapagos as CFO in June 2009. As CFO, Guillaume has
played an important role in financings, corporate transactions, and daily
financial management. With the recent sale of the service division to
Charles River, he played an important role in the transition of the Company
to now fully focus on the promising pipeline of clinical molecules and will
be leaving Galapagos to pursue other interests, effective on 1 May 2014.

Laure Verhaegen, head of the finance team, will act as interim CFO. She
joined Galapagos in May 2010 after more than 10 years in corporate finance,
external audit and controlling in Belgium and Luxembourg. While working in
Corporate Finance for Deloitte, she advised clients across multiple sectors
during their strategic transactions, including mergers&acquisitions and
project financing. Laure Verhaegen holds a master's degree in Business
Engineering obtained at ICHEC Brussels Management School and a degree in
Financial Analysis from the ABAF.

"Also on behalf of the Board of Directors, I wish to thank Guillaume for his
valuable contribution to strengthening Galapagos into one of the leading
biotechs in Europe. We wish him the best of luck with his future endeavors,"
added Onno van de Stolpe, CEO of Galapagos.

About Galapagos
Galapagos(Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action,
with a large pipeline comprising five Phase 2 studies (two led by GSK), one
Phase 1 study, six pre-clinical, and 20 discovery small-molecule and antibody
programs in cystic fibrosis, inflammation, antibiotics, metabolic disease,
and other indications. In the field of inflammation, AbbVie and Galapagos
signed a worldwide license agreement whereby AbbVie will be responsible for
further development and commercialization ofGLPG0634after Phase 2B. GLPG0634
is an orally-available, selective inhibitor of JAK1 for the treatment of
rheumatoid arthritis and potentially other inflammatory diseases, currently
in Phase 2B studies in RA and in Phase 2 in Crohn's disease. Galapagos has
another selective JAK1 inhibitor in Phase 2 in ulcerative colitis and
psoriasis, GSK2586184 (formerly GLPG0778, in-licensed by GlaxoSmithKline in
2012). GLPG0974is the first inhibitor of FFA2 to be evaluated clinically for
the treatment of IBD; this program is currently in a Proof-of-Concept Phase 2
study. GLPG1205is a first-in-class molecule that targets inflammatory
disorders and has completed Phase 1. AbbVie and Galapagos signed an
agreement in CF whereby they work collaboratively to develop and
commercialize oral drugs that address two mutations in the CFTR gene, the
G551D and F508del mutation. Potentiator GLPG1837 is at the pre-clinical
candidate stage. Galapagos has 400 employees, operating from its Mechelen,
Belgium headquarters and facilities in The Netherlands, France, and Croatia.
Further information at:www.glpg.com

CONTACT

Galapagos NV
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028
ir@glpg.com

This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will," "could,"
"stands to," and "continues," as well as similar expressions. Such
forward-looking statements may involve known and unknown risks, uncertainties
and other factors which might cause the actual results, financial condition,
performance or achievements of Galapagos, or industry results, to be
materially different from any historic or future results, financial
conditions, performance or achievements expressed or implied by such
forward-looking statements. Given these uncertainties, the reader is advised
not to place any undue reliance on such forward-looking statements. These
forward-looking statements speak only as of the date of publication of this
document. Galapagos expressly disclaims any obligation to update any such
forward-looking statements in this document to reflect any change in its
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statement is based, unless required by law or
regulation.

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Galapagos NV via Globenewswire

HUG#1780277

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.